Motion · S6M-04588 · 24 May 2022

Elasmogen Receives £8 Million Investment

Lodged by Liam Kerr (Scottish Conservative and Unionist Party) Standard Motion 29 supporters

The motion

That the Parliament congratulates Elasmogen for receiving an £8 million boost to help with what it sees as its pioneering research; notes that Elasmogen is a life science company based in Aberdeen, which, it understands, is currently developing drugs based on antibody-like molecules from sharks; understands that its soloMER binders are helping to create the next generation of biologics for inflammatory, autoimmune diseases and oncology, and reportedly have the potential to significantly improve the health of people in Scotland; applauds the work they are undertaking; understands that the biologics being developed are believed to be 10 times more effective than existing therapies for conditions including some cancers, rheumatoid arthritis and inflammatory bowel disease, and wishes all involved with what it sees as this ground-breaking work at Elasmogen all the best for the future.

Supporters (29)

Source: the Scottish Parliament motions and amendments record.